Direct cost assessments in subjects with seasonal allergic rhinitis living in Ankara, Turkey

Allergy and Asthma Proceedings

Volumn 25, Issue 2, 2004, Pages 107-113

  Çelik, Gülfem ^a,b   Mungan, Dilşad ^a   Abadoǧlu, Öznur ^a   Pinar, N Münevver ^a   Misirligil, Zeynep ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Faculty of Science ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; CETIRIZINE; FEXOFENADINE; FLUTICASONE PROPIONATE; LORATADINE; MOMETASONE FUROATE; STEROID;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; EDUCATION; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; TURKEY (REPUBLIC);

ADULT; DIRECT SERVICE COSTS; DRUG COSTS; FEMALE; HUMANS; MALE; POACEAE; POLLEN; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TURKEY;

EID: 2442424184     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Charpin D, Sibbald B, Weeke E, and Wutrich B. Epidemiologic identification of allergic rhinitis. Allergy 51:293-298, 1996.
2. Lundbäck B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 28:3-10, 1998.
3. Çelik G, Mungan D, Bavbek S, et al. The prevalence of allergic diseases and atopy in Ankara, Turkey: a two-step population-based epidemiological study. J Asthma 36:281-290, 1999.
4. Kalyoncu AF, Selçuk ZT, Karakoca Y, et al. Prevalence of childhood asthma and allergic diseases in Ankara, Turkey. Allergy 49:485-488, 1994.
5. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 99:S22-S27, 1997.
6. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 73:35-39, 1994.
7. Weiss KB. Cost implications of upper respiratory allergic diseases. J Allergy Clin Immunol 101:S308-S385, 1998.
8. European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. Allergy 55:116-134, 2000.
9. van Cauwenberge P, Lund V, Bousquet J, et al. Profiles and symptom severity of patients presenting to general practice with seasonal allergic rhinitis. J Allergy Clin Immunol 104:S390, 2000.
10. Inceoglu O, Pinar NM, Sakiyan N, et al. Airborne pollen concentration in Ankara, Turkey 1990-1993. Grana 33:158-161, 1994.
11. Özkaragöz K, and Karamanoǧlu K. Allergenic pollen and mold spore survey in the Ankara area. Acta Allergol 22:399-407, 1967.
12. Pollart SM, Reid MJ, Fling JA, et al. Epidemiology of emergency room asthma in northern California: association with IgE antibody to rye grass pollen. J Allergy Clin Immunol 82:224-230, 1988.
13. Knox RB. Grass pollen, thunderstorms, and asthma. Clin Exp Allergy 23:354-359, 1993.
14. Ferguson BJ. Cost-effective pharmacotherapy for allergic rhinitis. Otolaryngeal Clin North Am 31:91-110, 1998.
15. Santos R, Cifaldi M, Gregory C, et al. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Manag Care 5:S225-S234, 1999
16. Trotter JP. The treatment of seasonal allergic rhinitis: cost implications of pharmacotherapy for managed care. Manag Care Interface 13:60-62, 2000.
17. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 21:7-13, 2000.
18. Stahl E, van Rompay W, Wang EC, et al. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. An Allergy Asthma Immunol 84:397-402, 2000.
19. Kozma CM, Sadik MK, and Watrous ML. Economic outcomes for the treatment of allergic rhinits. Pharmacoeconomics 10:4-13, 1996.
20. Socio-economic costs of allergic diseases. In, Allergic Diseases as a Public Health Problem, European Allergy White Paper. Moerbeke DV (Ed). Brussels, Belgium: The UCB Institute of Allergy, 98-110, 2002.
21. Kalyoncu AF, Karakoca Y, Demir AU, et al. Prevalence of asthma and allergic disease in Turkish university students in Ankara. Allergol Immunopathol (Madr) 24:152-157, 1996.
22. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 82:296-305, 1999.
23. Specor S. Ideal pharmacotherpy for allergic rhinitis. J Allergy Clin Immunol 103:S386-S387, 1999.
24. Nash DB, Sullivan SD, and Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinits in a managed care setting. Am J Manag Care 6:S3-S15, 2000.
25. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 88(suppl):2-7, 2002.
26. Storms WW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 88(suppl):30-35, 2002.